PAVM - PAVmed Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.38
-0.02 (-1.43%)
At close: 4:00PM EDT

1.35 -0.03 (-2.17%)
After hours: 5:48PM EDT

Stock chart is not supported by your current browser
Previous Close1.40
Open1.39
Bid1.36 x 800
Ask1.42 x 1000
Day's Range1.33 - 1.42
52 Week Range0.87 - 9.31
Volume869,381
Avg. Volume576,325
Market Cap36.583M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.77
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
Trade prices are not sourced from all markets
  • Business Wire6 days ago

    PAVmed Names Shaun O’Neil Chief Commercial Officer

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that it has named Shaun M. O’Neil to serve as its first Chief Commercial Officer. Mr. O’Neil will oversee all aspects of the domestic and international commercialization of PAVmed’s products including sales and marketing, clinician engagement and professional education.

  • Business Wire8 days ago

    Nasdaq Notifies PAVmed of Regained Compliance with Continued Listing Requirements

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has notified the Company that it has regained compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1). On June 27, 2018, PAVmed filed a Form 8-K with the Securities and Exchange Commission announcing that it believed its recently closed oversubscribed equity subscription rights offering, raising gross proceeds of approximately $10.35 million, allowed the Company to regain compliance with Nasdaq’s minimum $2.5 million stockholders’ equity requirement for continued listing as set forth in Listing Rules 5550(b)(1).

  • Business Wire20 days ago

    PAVmed Provides Business Update

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided a business update following its recently closed, oversubscribed rights offering. “During our recently completed rights offering we had the pleasure of meeting with many existing investors as well as new investors who were learning about PAVmed for the first time,” said Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer. “A common theme during these interactions and subsequent inquiries from investors has been a strong interest in more frequent updates from the Company as we progress towards important milestones.

  • GlobeNewswirelast month

    Dawson James Securities Announces the Closing of Oversubscribed $10,350,000 Rights Offering for PAVmed, Inc.

    BOCA RATON, Fla., June 13, 2018-- Dawson James Securities, Inc. and Maxim Group LLC acted as dealer-managers on an oversubscribed equity subscription rights offering for PAVmed Inc. which raised the maximum ...

  • Business Wirelast month

    PAVmed Closes Oversubscribed Rights Offering for Gross Proceeds of $10,350,000

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced the closing of its oversubscribed equity subscription rights offering (the “Rights Offering”), which raised the maximum gross proceeds of $10,350,000. Pursuant to the Rights Offering, PAVmed’s stockholders exercised and the Company accepted equity subscription rights resulting in the issuance of 9 million units that consisted of one share of common stock and one Series Z Warrant. Each right entitled the holder to purchase one unit at a subscription price of $1.15 per unit, with each unit consisting of one share of common stock (PAVM) and one Series Z Warrant (PAVMZ) to purchase one share of common stock with an exercise price of $1.60.

  • Business Wirelast month

    PAVmed to Receive $10.4 Million in Gross Proceeds from Oversubscribed Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced its previously announced equity subscription rights offering (the “Rights Offering”) expired at 5:00 p.m. Eastern Time on Thursday, June 7, 2018 and, as such, the rights are no longer exercisable. The Company received subscriptions that exceeded the number of rights available to be exercised under the Rights Offering and has accepted all valid subscriptions including up to 9 million units of the total oversubscribed amount. Allocations will be determined in accordance with the provisions disclosed in the Company’s registration statement on Form S-1 as filed with the Securities Exchange Commission (“SEC”) (SEC File No. 333-222581).

  • What Investors Should Know About PAVmed Inc’s (NASDAQ:PAVM) Financial Strength
    Simply Wall St.last month

    What Investors Should Know About PAVmed Inc’s (NASDAQ:PAVM) Financial Strength

    While small-cap stocks, such as PAVmed Inc (NASDAQ:PAVM) with its market cap of US$17.16M, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...

  • Business Wire2 months ago

    PAVmed Updates the Terms of Previously Announced Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that its board of directors has approved the following changes to its previously announced rights offering: (i) the common stock and Series Z Warrants included in the units will now be tradeable immediately upon their issuance, and (ii) the subscription price shall be $1.15 per unit. Each right now entitles the holder to purchase one unit at the subscription price of $1.15 per unit and each unit remains comprised of one share of the Company’s common stock and one Series Z Warrant. The record date for the rights offering remains May 21, 2018 and the subscription rights are still non-transferrable and may only be exercised during the subscription period.

  • Business Wire2 months ago

    PAVmed Updates Expected Key Dates for Previously Announced Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, previously announced on May 8, 2018 that the Company had filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company.

  • Business Wire2 months ago

    PAVmed Reports First Quarter 2018 Financial Results

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today reports financial results for the three months ended March 31, 2018 and provides a business update.

  • Business Wire2 months ago

    PAVmed Inc. to Hold Business Update Conference Call on May 30, 2018

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, May 30, 2018 at 4:30 p.m. Eastern time. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s Chief Financial Officer, will discuss first quarter 2018 financial results.

  • Business Wire2 months ago

    PAVmed Announces Adjustment to Series Z Warrant Exercise Price

    PAVmed Inc. (Nasdaq: PAVM, PAVMW)) (“PAVmed”), a highly differentiated, multiproduct medical device company, announced today that its board of directors approved a reduction to the exercise price of its Series Z Warrants (CUSIP number 70387R122) (the “Series Z Warrants”) that trade under the symbol “PAVMZ” on the Nasdaq Capital Market from $3.00 per share to $1.60 per share. The effective date of the exercise price reduction will be June 1, 2018. PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company.

  • Business Wire2 months ago

    PAVmed and Case Western Reserve University Finalize Definitive Licensing Agreement for Groundbreaking EsoCheck Technology

    PAVmed Inc. (Nasdaq:PAVM, PAVMZ), a highly differentiated, multi-product medical device company, today announced it has finalized a definitive licensing agreement with Case Western Reserve University to develop and commercialize its groundbreaking EsoCheck technology. EsoCheck is a rapid office-based alternative to diagnostic endoscopy that combines a non-invasive cell sampling device with a DNA biomarker test. Together these have been shown to be highly accurate in detecting Barrett’s Esophagus, the primary precursor to the most common and lethal form of esophageal cancer caused by Gastroesophageal Reflux Disease (GERD), commonly known as heart burn or acid reflux.

  • Business Wire2 months ago

    PAVmed Sets Record Date for Previously Announced Rights Offering

    PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that the Company has filed a preliminary prospectus as part of a registration statement on Form S-1 with the Securities and Exchange Commission for a rights offering (the “Rights Offering”) to stockholders of record on Monday, May 21, 2018. Under the proposed Rights Offering, the Company will distribute non-transferable subscription rights to purchase a new unit (the “Unit”) for each share of Common Stock outstanding, at a subscription price per Unit of $2.25, to its stockholders on the record date.

  • Business Wire3 months ago

    PAVmed Signs Letter of Intent with Case Western Reserve University to Commercialize Groundbreaking EsoCheck Technology

    PAVmed Inc. , a highly differentiated, multi-product medical device company, today announced that it has signed a letter of intent with Case Western Reserve University to commercialize its groundbreaking EsoCheck technology.

  • Business Wire3 months ago

    PAVmed Reports Fourth Quarter and Full Year 2017 Financial Results

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.

  • Business Wire3 months ago

    PAVmed Announces Final Results of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the final results of its previously disclosed offer to exchange each of its Series W Warrants for 0.5 Series Z Warrants .

  • Business Wire3 months ago

    PAVmed Inc. to Hold Business Update Conference Call on April 11, 2018

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that the Company will host a conference call on Wednesday, April 11, 2018 at 4:30 p.m.

  • Business Wire3 months ago

    PAVmed Announces Preliminary Results of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the preliminary results of its previously disclosed offer to exchange each of its Series W Warrants for 0.5 Series Z Warrants .

  • ACCESSWIRE3 months ago

    Pavmed to Present at The Microcap Conference

    NEW YORK, NY / ACCESSWIRE / April 2, 2018 / PAVmed Inc. (NASDAQ: PAVM)(NASDAQ: PAVMW) (the ''Company''), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, ...

  • Business Wire4 months ago

    PAVmed Announces Extension of Offer to Exchange Series W Warrants for Series Z Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that its previously disclosed offer to exchange Series W Warrants for Series Z Warrants has been extended, in accordance with applicable rules and regulations governing tender offers, until 5:00 P.M., Eastern Time, on April 2, 2018, unless further extended or terminated.

  • Business Wire4 months ago

    PAVmed to Present at the 28th Annual Oppenheimer Healthcare Conference

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m.

  • Who Are The Major Shareholders In PAVmed Inc (NASDAQ:PAVM)?
    Simply Wall St.5 months ago

    Who Are The Major Shareholders In PAVmed Inc (NASDAQ:PAVM)?

    Today, I will be analyzing PAVmed Inc’s (NASDAQ:PAVM) recent ownership structure, an important but not-so-popular subject among individual investors. A company’s ownership structure is often linked to its share performanceRead More...

  • Business Wire5 months ago

    PAVmed Initiates Offer to Exchange Outstanding Warrants

    PAVmed Inc. , a highly differentiated, multiproduct medical device company, today announced the filing of a warrant exchange offer with the U.S.

  • Is PAVmed Inc (NASDAQ:PAVM) Overpaying Its CEO?
    Simply Wall St.5 months ago

    Is PAVmed Inc (NASDAQ:PAVM) Overpaying Its CEO?

    Lishan Aklog took the reins as CEO of PAVmed Inc’s (NASDAQ:PAVM) and grew market cap to US$27.87M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...